Dimerix (ASX:DXB) files patent family application for COPD candidate

Image Source: © Stuartbur | Megapixl.com


  • Dimerix has taken a crucial step towards bolstering its IP position.
  • The biopharmaceutical company has announced a new patent family application for DMX-700 for COPD.
  • DMX-700 achieved a statistically significant 80% reduction versus control in induced lung injury in mice.

ASX-listed biopharmaceutical company Dimerix Limited (ASX:DXB) has made a major headway with a new patent family application filed for its pipeline candidate, DMX-700. The patent is aimed at securing protection for key findings from the latest study focused on the treatment of Chronic Obstructive Pulmonary Disease (COPD).

This new patent application strengthens the existing global patent application of DMX-700, filed in Sept 2020. It is believed that DMX-700 will have a solid competitive position as it will be secured by Formulation patents, Composition of Matter Patents, and Method of Use patents.

Dosage regimen for the treatment of COPD

The patent filing follows a latest study wherein DMX-700 achieved a statistically significant 80% reduction versus control in induced lung injury in mice.

On a surprising note, the study also demonstrated that the use of an IL-8Rβ inhibitor combined with specific doses of an angiotensin type 1 receptor blocker (ARB) was more efficient in treatment of COPD related lung injury.

The new provisional patent application, titled "Dosage regimen for the treatment of COPD," with the Australian number 2022902171, has a priority date of 02 August 2022, and if granted, would expire after 2043. This patent application won't go public for about 18 months following the priority date, as is customary in the prosecution of patents.

Each DMX-700 compounds have a known safety profile in human trials, which suggests DMX-700 may enter clinical investigations, subject to approvals from concerned regulatory authorities. Now that the clinical trial is expected to be designed, along with any other non-clinical safety investigations that may be necessary, the initial clinical research is anticipated to begin in the first half of 2023.

Know more about DMX-200

DMX-200, another proprietary product of Dimerix, is under study to treat Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, and Diabetic kidney disease.

Stock information

Dimerix has a market capitalisation of AU$51.33M. At the time of writing this article (Tue, 09 Aug, 11:08 AM, AEST), the share price of Dimerix stood at AU$0.160. 

In the last one month, the shares have gained over 14%.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and